Literature DB >> 25766356

A novel option for treatment of primary axillary hyperhidrosis: fractionated microneedle radiofrequency.

F Fatemi Naeini, M Pourazizi, B Abtahi-Naeini1, M A Nilforoushzadeh, J Najafian.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 25766356      PMCID: PMC4943439          DOI: 10.4103/0022-3859.153111

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


× No keyword cloud information.
Sir Hyperhidrosis is a common ailment which greatly affects quality of life. There are several treatment options, but there is a lack of consensus and clear guidelines for treatment of these patients.[12] Medical (e.g., Botulinum toxin type A) and surgical treatments have been used to control or reduce excessive sweating with variable success.[345] Only surgical modalities have been capable of conferring a permanent solution.[4] Recently, few studies have been done for clinical evaluation of radiofrequency (RF) energy in the treatment of primary axillary hyperhidrosis(PAH).[67] But there is limited published evidence. We report in this paper, successful treatment of refractory PAH with fractionated microneedle radiofrequency (FMR) in a 29-year-old female patient, confirmed with routine histopathological staining. A 29-year-old female patient had severe recalcitrant bilateral axillary hyperhidrosis since puberty (grade 4 in Hyperhidrosis Disease Severity Scale). Personal history was otherwise uneventful. The patient identified many triggers such as emotion, temperature, or physical effort for the hyperhidrosis that occurred in more than ten attacks per day. Topical treatment with aluminium chloride had produced an unsatisfactory response and she stopped the use of this agent 6 months prior to meeting us for treatment. Systemic therapy using an anticholinergic preparation had to be stopped because of adverse effects. Botulinum toxin type A was used in the affected area in frequent sessions with limited results. We then started the patient on four treatment sessions of FMR (INFINI; Lutronic, Goyang, Korea) at 2-week intervals [Figure 1]. Results of the Iodine starch test (Minor sweat test) are shown in Figure 2. The INFINI procedure is performed in foursteps [Figure 3]. After marking the area to be treated, a topical eutectic mixture of 2.5% lidocaine hydrochloric acid and 2.5% prilocaine (EMLA; Astra- Zeneca, Sodertalje, Sweden) was applied to the axilla under occlusion 30 minutes before therapy. The treatment settings were 2.5-to 3-mm Microneedle penetrating depth, 6 to 9 level intensity, and 140- to 180-ms RF time. Multiple placements with the hand piece are required to deliver Microneedle RF [Figure 3]. Immediately after treatment minimal undesirable effects such as mild skin irritation and erythema and pin point bleeding were noted [Figure 3] but none were so severe as to cause termination of treatment. Results of the Iodine starch test after treatment are shown in Figure 4. During the 6 month follow-up, the patient had no complaints of hyperhidrosis. The FMR is a minimally invasive method for delivering thermal energy to the target tissue without destroying the epidermis, by using rapid penetration with microneedle. This treatment has demonstrated excellent efficacy for skin rejuvenation, face lifting, large pores and acne scars.[89] The novel bipolar radiofrequency device can destroy eccrine glands which are considered as a thermolysis at the interface of the deep dermis and subcutis, minimizing damage to surrounding tissue. The results demonstrate that microwave technology is well suited for targeting sweat glands while allowing for protection of both the upper skin layers and the structures beneath the subcutaneous fat.[10] The mechanism of reduced hyperhidrosis by way of the radiofrequency device is that the sweat glands are destroyed by heating the interface where they are located, that is, the hypodermal interface. Therefore, the device works by heating and cooling at the same time.[71011] The radiofrequency from the tips of the microneedles causes direct thermal injury which decreases the size and density of the apocrine glands.[12] In our patient, a clear reduction of viable sweat gland structures was seen when her before treatment (“baseline”) sample was compared with the follow-up time samples. There was no significant histopathologic evidence of adverse effects on other cutaneous structures in this study. Thus, FMR can be considered as a safe, effective and non-invasive technique for treatment of primary axillary hyperhidrosis but more studies are needed to confirm the persistent effect and histopathological alternation during treatment with FMR.
Figure 1

The INFINI console, headpiece. (INFINI; Lutronic, Goyang, Korea)

Figure 2

Starch-iodine tests. Starch-iodine photographs of the left axilla of subject at baseline (blue-black sedimentation)

Figure 3

Procedure description. The INFINI procedure is performed in foursteps. (a) Step 1 –sizing the area to be treated and marking that area after starch-iodine test. (b) Step 2 –Topical anaesthesia under occlusion. (c) Step 3 –place hand piece on designated areas to deliver the therapy. (d) Step 4 –dressing with sterile vaseline gauzes

Figure 4

Starch-iodine test. Normal results of starch-iodine testafter foursessions of fractionated microneedle radiofrequency. (Wight sedimentation)

The INFINI console, headpiece. (INFINI; Lutronic, Goyang, Korea) Starch-iodine tests. Starch-iodine photographs of the left axilla of subject at baseline (blue-black sedimentation) Procedure description. The INFINI procedure is performed in foursteps. (a) Step 1 –sizing the area to be treated and marking that area after starch-iodine test. (b) Step 2 –Topical anaesthesia under occlusion. (c) Step 3 –place hand piece on designated areas to deliver the therapy. (d) Step 4 –dressing with sterile vaseline gauzes Starch-iodine test. Normal results of starch-iodine testafter foursessions of fractionated microneedle radiofrequency. (Wight sedimentation)
  12 in total

Review 1.  Radiofrequency in cosmetic dermatology: a review.

Authors:  Margarita S Lolis; David J Goldberg
Journal:  Dermatol Surg       Date:  2012-08-22       Impact factor: 3.398

2.  The effect of ambient humidity on transepidermal water loss.

Authors:  K Grice; H Sattar; H Baker
Journal:  J Invest Dermatol       Date:  1972-06       Impact factor: 8.551

3.  Evaluation of the clinical efficacy of fractional radiofrequency microneedle treatment in acne scars and large facial pores.

Authors:  Soo Ick Cho; Bo Young Chung; Min Gyu Choi; Ji Hwoon Baek; Hee Jin Cho; Chun Wook Park; Cheol Heon Lee; Hye One Kim
Journal:  Dermatol Surg       Date:  2012-04-09       Impact factor: 3.398

Review 4.  Treatment of hyperhidrosis with botulinum toxin.

Authors:  Melissa A Doft; Krista L Hardy; Jeffrey A Ascherman
Journal:  Aesthet Surg J       Date:  2012-02       Impact factor: 4.283

5.  Botulinum toxin.

Authors:  P K Nigam; Anjana Nigam
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

6.  The efficacy of a microwave device for treating axillary hyperhidrosis and osmidrosis in Asians: a preliminary study.

Authors:  Sang-Jun Lee; Ka-Yeun Chang; Dong-Hye Suh; Kye-Yong Song; Hwa Jung Ryu
Journal:  J Cosmet Laser Ther       Date:  2013-06-21       Impact factor: 2.247

7.  Patient's estimation of efficacy of various hyperhidrosis treatments in a dermatological clinic.

Authors:  Mohammad Amini; Ankie M Harmsze; Ron A Tupker
Journal:  Acta Derm Venereol       Date:  2008       Impact factor: 4.437

8.  A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee.

Authors:  Nowell Solish; Vince Bertucci; Alain Dansereau; H Chih-Ho Hong; Charles Lynde; Mark Lupin; Kevin C Smith; Greg Storwick
Journal:  Dermatol Surg       Date:  2007-08       Impact factor: 3.398

9.  Efficacy of fractional microneedle radiofrequency device in the treatment of primary axillary hyperhidrosis: a pilot study.

Authors:  Miri Kim; Jae Yong Shin; Jungsoo Lee; Ji Young Kim; Sang Ho Oh
Journal:  Dermatology       Date:  2013-10-04       Impact factor: 5.366

10.  A case of idiopathic unilateral circumscribed hyperhidrosis.

Authors:  Hari Kishan Kumar Yadalla; H Ambika; Simran Chawla
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

View more
  6 in total

1.  Radiofrequency in the treatment of primary hyperhidrosis: systematic review and meta-analysis.

Authors:  Fabio Nishida Hasimoto; Daniele Cristina Cataneo; Erica Nishida Hasimoto; Aglaia Moreira Garcia Ximenes; Antônio José Maria Cataneo
Journal:  Clin Auton Res       Date:  2019-09-24       Impact factor: 4.435

Review 2.  Optimal targeting of sympathetic chain levels for treatment of palmar hyperhidrosis: an updated systematic review.

Authors:  Hai-Wei Sang; Guo-Liang Li; Peng Xiong; Ming-Chuang Zhu; Min Zhu
Journal:  Surg Endosc       Date:  2017-04-07       Impact factor: 4.584

3.  Quality of life in patients with primary axillary hyperhidrosis before and after treatment with fractionated microneedle radiofrequency.

Authors:  Bahareh Abtahi-Naeini; Farahnaz Fatemi Naeini; Neda Adibi; Mohsen Pourazizi
Journal:  J Res Med Sci       Date:  2015-07       Impact factor: 1.852

4.  Treatment of Primary Axillary Hyperhidrosis by Fractional Microneedle Radiofrequency: Is it Still Effective after Long-term Follow-up?

Authors:  Bahareh Abtahi-Naeini; Farahnaz Fatemi Naeini; Ali Saffaei; Shadi Behfar; Mohsen Pourazizi; Majid Mirmohammadkhani; Najmeh-Sadat Bolandnazar
Journal:  Indian J Dermatol       Date:  2016 Mar-Apr       Impact factor: 1.494

5.  Promising Option for Treatment of Striae Alba: Fractionated Microneedle Radiofrequency in Combination with Fractional Carbon Dioxide Laser.

Authors:  Farahnaz Fatemi Naeini; Shadi Behfar; Bahareh Abtahi-Naeini; Shima Keyvan; Mohsen Pourazizi
Journal:  Dermatol Res Pract       Date:  2016-03-16

6.  Can Fractionated Microneedle Radiofrequency be an Effective Procedure for Treatment of Fox-Fordyce Disease? A Medical Hypothesis.

Authors:  Sattar Kabiri; Mohsen Pourazizi; Bahareh Abtahi-Naeini
Journal:  Adv Biomed Res       Date:  2018-04-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.